Inalacor Accuhaler (Fluticasone Propionate)

Fluticasone propionate binds to glucocorticoid receptors inside airway cells, altering gene expression to suppress the release of inflammatory mediators such as cytokines and chemokines. This reduces airway swelling, mucus production, and hyper‑responsiveness, leading to improved airflow and fewer asthma or COPD symptoms.

The appropriate dose of Inalacor Accuhaler is determined by a qualified prescriber based on the patient’s age, disease severity, and response to therapy. Healthcare professionals tailor the number of inhalations per day to achieve optimal control while minimizing potential side effects.

Safety data for fluticasone propionate in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Pregnant or nursing patients should discuss treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Inalacor Accuhaler. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Inalacor Accuhaler delivers fluticasone propionate, a high‑potency corticosteroid with strong anti‑inflammatory activity. Compared with agents such as budesonide, fluticasone generally requires a lower daily dose to achieve similar clinical effects, but both classes share comparable safety profiles when used at recommended doses.

Store the inhaler at ambient temperature, away from direct sunlight and moisture. Keep it in the original packaging until use, and avoid exposing it to extreme heat or humidity. Do not refrigerate or freeze the device, as this could affect powder integrity.

To use the dry‑powder inhaler, remove the cap, exhale fully away from the device, place the mouthpiece between the lips, and inhale sharply and deeply. Hold the breath for about 10 seconds, then remove the inhaler and breathe out gently. Rinse the mouth after each dose to reduce the risk of oral thrush.

Serious adverse events, although rare, include paradoxical bronchospasm, adrenal suppression, severe allergic reactions such as anaphylaxis, and opportunistic infections like pneumonia. Patients should seek immediate medical attention if they experience sudden breathing difficulty, severe swelling, or signs of infection.

Inalacor Accuhaler is contraindicated in individuals with a known hypersensitivity to fluticasone propionate or any component of the inhaler. It should also be avoided in patients with untreated systemic fungal infections or those who have experienced a severe reaction to other inhaled corticosteroids.